awmsg logo



zanamivir (Dectova®)


Reference No. 4130

Publication date:
25/10/2019


Appraisal information

zanamivir (Dectova®) 10 mg/ml solution for infusion


Company: GlaxoSmithKline UK
BNF category: Infections
NMG meeting date: 04/09/2019
AWMSG meeting date: 16/10/2019
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1219
Ratification by Welsh Government: 22/10/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Zanamivir (Dectova®) is recommended as an option for use within NHS Wales for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Zanamivir (Dectova®) should be used in accordance with official guidance.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download